Europe medicine regulator has recommended the suspension of over 300 generic drug approvals& drug applications as due to unreliable tests been taken by Indian contract research firm Micro Therapeutic Research Labs. Europe medicine regulator has recommended the suspension of over 300 generic drug approvals& drug applications as due to unreliable tes
Findings from Huazhong University of Science and Technology Has Provided New Information about Colon Cancer. By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Research findings on Oncology- Colon Cancer are discussed in a new report. According to news reporting originating in Hubei, People's Republic of China, by NewsRx journ
A pharmaceutical company based in Delhi, Mankind Pharma, which is recognised for its contraceptive products, is now ready to plunge into the diagnostic laboratories business with Pathkind. The Company wants to utilise the opportunity that Dr Lal Path Labs, Metropolis and SRL Diagnostics have created to make the sector more structured. For venturing
By a News Reporter-Staff News Editor at VerticalNews Health A majority of patients in the United States visited a doctor who received payments from drug companies, but most have no clue about it, according to a new Drexel University study. About 65 percent of those surveyed as a part of the study by Genevieve Pham-Kanter, PhD, an assistant profes
Health care workers shout slogans during a demonstration over the lack of medicines and low salaries in the country, in Caracas on February 7, 2017. Venezuelan President Nicolas Maduro said on Friday he has asked the United Nations to help the South American nation alleviate medicine shortages, which have become increasingly severe as the oil-produ
Alder BioPharmaceuticals Inc. insider Mark James Litton sold 1,498 shares of the stock in a transaction on Wednesday, January 18th. Shares of Alder BioPharmaceuticals Inc. opened at 21.00 on Monday. Alder BioPharmaceuticals Inc. has a 52 week low of $15.82 and a 52 week high of $36.48.
Analyst Ratings For CymaBay Therapeutics (NASDAQ:CBAY) Today, Piper Jaffray Companies raised its price target on CymaBay Therapeutics (NASDAQ:CBAY) to per share. There are 2 buy ratings on the stock. The current consensus rating on CymaBay Therapeutics (NASDAQ:CBAY) is Buy (Score: 3.00) with a consensus target price of $6.25 per share, a potential
PINEHURST, N.C, March 25, 2017/ PRNewswire-iReach/ With the worldwide growth of the nutritional supplement industry, Assisi Animal Health, developer of the Assisi Loop , an effective non-pharmaceutical anti-inflammatory device that works as a PEMF therapy for animals, lists supplements to keep away from pets. Known as the Vitamins, Minerals, an
-Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Companys cancer immunotherapy Imprime PGG in combination with Erbitux and chemotherapy in metastatic non-small cell lung cancer patients. Completed by Biothera in 2013, the study was part of an early series of clinical.
Cyclenium Pharma Announces a Research Collaboration with The Hospital for Sick Children to Identify Novel Macrocyclic Modulators for Pharmacological Targets in Multiple Therapeutic Areas. By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery.
The details of the plans were listed out in a Cabinet paper presented by Prime Minister Ranil Wickremesinghe this week, which was approved. Under the proposals approved by Cabinet the Health Ministry will gazette a list of plants, machinery, equipment, packaging and raw materials used by the pharmaceutical industry. The Megapolis and Western Develo
Europe's medicines regulator has recommended the suspension of more than 300 generic drug approvals and drug applications due to "unreliable" tests conducted by Indian contract research firm Micro Therapeutic Research Labs. The decision, announced by the European Medicines Agency on its website, is the latest blow for India's drug-testing industry,
The inter-ministerial body, to be wound up soon, recommended to the Cabinet Committee on Economic Affairs a proposal by Apollo Hospitals to raise fresh equity shares for Rs 750 crore through foreign investment. China`s Shanghai Fosun planned to acquire 86 per cent stake in India`s Gland Pharmaceuticals last year in July. Fosun had worked out a clea
A French pharmaceutical company specialised in generic and biosimilar medicines, and a subsidiary of Servier, on Friday announced the takeover of all the activities of Swipha, a Nigerian company that manufactures and distributes pharmaceutical products known for their quality. This is an important step forward in the internationalisation of the Fre
By a News Reporter-Staff News Editor at Investment Weekly News Research and Markets has announced the addition of the "Over-the-Counter Drugs and Dietary Supplements: Global Markets" report to their offering. The global market for over the counter drugs and dietary supplements reached $164.7 billion in 2016 and should reach $220.8 billion in 2021
It s been a bad week for Google, with major brands pulling millions of dollars in advertising amid rows over extremist content on YouTube.. In America, telecom companies AT&T and Verizon, as well as pharmaceutical company GSK, Pepsi, Walmart, Johnson& Johnson and car rental firm Enterprise, have all pulled advertising from Google s video shar
European Society for Blood and Marrow Transplantation 2017- Marseille, FranceMarch 27, 2017, 9:00- 9:10am Oral Session 3: Novel drugs and immunotherapies Title: Drug Resistant Lymphocyte Immunotherapy: Dose and Schedule OptimizationPresenter: Lawrence Lamb. American Association for Cancer Research 2017- Washington DC, USAApril 3, 2017, 8:00- 12:00p
Insider Trading Activity For Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Michael Bonner , CFO of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) reportedly Bought 900 shares of the company's stock at an average price of 6.42 for a total transaction amount of $5,778.00 SEC Form Insider Trading History For Cumberland Pharmaceuticals, Inc. (NASDAQ
Insider Trading Activity For Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Steven L Krill , EVP of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) reportedly Sold 14,125 shares of the company's stock at an average price of 81.07 for a total transaction amount of $1,145,113.75 SEC Form Insider Trading History For Eagle Pharmaceuticals Inc (NASDAQ:EGRX) On 2/18/
THE introduction of Delamanid, a Japanese manufactured drug, has ushered in new hope in the fight against multidrug-resistant tuberculosis in South Africa. Delamanid, manufactured by pharmaceutical company, Otsuka, will initially be made available to 400 patients in South Africa as part of a clinical access research project. "We have again moved r
Attorney Advertising. On March 17, 2017, the nationally recognized class-action law firm of Keller Rohrback L.L.P. filed suit against the nation s three largest pharmacy benefit managers, Express Scripts, OptumRx, and CVS Caremark, and the three major insulin manufacturers, Sanofi-Aventis, Novo Nordisk, and Eli Lilly, who produce the well-known
It received final approval for its Tobramycin Inhalation Solution USP, 300 mg/5 ml from US Food and Drug Administration to market a generic version of Novartis Pharmaceuticals` TOBI 300 mg/5 ml. Lupin has the fifth largest pipeline of ANDA filings pending approval with US FDA 134 product filings pending approval. Cumulative Filings with the US FD
-Neuren Pharmaceuticals has reported top-line results for its Phase 2 clinical trial in girls with Rett syndrome aged 5 to 15. Neuren now intends to discuss with the US Food and Drug Administration plans for a pivotal trial commencing in 2018 using the Rett Syndrome Behaviour Questionnaire as a primary efficacy measure, supported by the Clinical Gl
Neuro-Bio Ltd, a UK- based early stage biopharmaceutical company focussing on neurodegenerative diseases, today announced it has received Series A funding of $3.2 million from US-based Kairos Ventures to continue developing a diagnostic tool for early detection of Alzheimer`s and to discover new drugs targeting the disease. Professor Margaret Esiri